106. Cryopyrin-associated periodic syndrome Clinical trials / Disease details
Clinical trials : 42 / Drugs : 24 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00069329 (ClinicalTrials.gov) | September 2003 | 22/9/2003 | Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease | A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease | Nervous System Malformations;Arthropathy, Neurogenic;Urticaria;Papilledema | Drug: anakinra | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NULL | Terminated | N/A | N/A | All | 43 | Phase 1/Phase 2 | United States |
| 2 | EUCTR2013-000300-42-Outside-EU/EEA (EUCTR) | 18/01/2013 | A long-term study with the IL-1 receptor blocker anakinra/kineret® in patients with neonatal onset multisystem inflammatory disease (NOMID/CINCA syndrome) | A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome) | neonatal onset multisystem inflammatory disease (NOMID/CINCA);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Kineret | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NULL | NA | Female: yes Male: yes | 50 | United States |